CRIS Current Research Information System

PECCI, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.157
NA - Nord America 520
EU - Europa 225
SA - Sud America 55
Continente sconosciuto - Info sul continente non disponibili 51
AF - Africa 20
OC - Oceania 2
Totale 2.030
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 492
CN - Cina 320
SG - Singapore 304
VN - Vietnam 259
HK - Hong Kong 96
IT - Italia 90
KR - Corea 46
BR - Brasile 43
BD - Bangladesh 39
DE - Germania 30
IN - India 30
NL - Olanda 30
FI - Finlandia 21
CA - Canada 14
JP - Giappone 14
FR - Francia 11
AR - Argentina 9
AT - Austria 8
ID - Indonesia 8
RU - Federazione Russa 7
BE - Belgio 6
GB - Regno Unito 6
PH - Filippine 6
TH - Thailandia 6
CI - Costa d'Avorio 5
IQ - Iraq 5
MX - Messico 5
PK - Pakistan 4
AE - Emirati Arabi Uniti 3
IL - Israele 3
JM - Giamaica 3
LT - Lituania 3
PL - Polonia 3
SC - Seychelles 3
TW - Taiwan 3
AU - Australia 2
BG - Bulgaria 2
ES - Italia 2
HN - Honduras 2
KE - Kenya 2
NI - Nicaragua 2
NP - Nepal 2
SA - Arabia Saudita 2
TR - Turchia 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BY - Bielorussia 1
CH - Svizzera 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
GA - Gabon 1
GR - Grecia 1
IE - Irlanda 1
JO - Giordania 1
LY - Libia 1
MA - Marocco 1
ML - Mali 1
MY - Malesia 1
NG - Nigeria 1
PR - Porto Rico 1
SE - Svezia 1
SN - Senegal 1
TJ - Tagikistan 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZA - Sudafrica 1
Totale 1.981
Salva come PNG Salva come JPEG
Città #
Singapore 214
Hefei 114
Hong Kong 91
Ashburn 89
San Jose 72
Hanoi 66
Ho Chi Minh City 66
Santa Clara 53
Seoul 43
Council Bluffs 34
Boardman 23
Beijing 21
Helsinki 20
Bologna 17
New York 17
São Paulo 15
Tokyo 13
Bengaluru 11
Buffalo 11
Los Angeles 11
Da Nang 10
Dallas 10
Haiphong 10
Shanghai 10
Falkenstein 9
Nuremberg 9
Frankfurt am Main 8
Hyderabad 8
Lauterbourg 8
San Francisco 8
The Dalles 8
Can Tho 7
Guangzhou 7
Jakarta 7
North Charleston 7
Redondo Beach 7
Orem 6
Verona 6
Abidjan 5
Biên Hòa 5
Indianapolis 5
Modena 5
Rome 5
Bình Phước 4
Ha Long 4
Hangzhou 4
Tongling 4
Wuhan 4
Amsterdam 3
Atlanta 3
Brussels 3
Bắc Giang 3
Chengdu 3
Denver 3
Harbin 3
Kingston 3
Montreal 3
Mumbai 3
Munich 3
Naples 3
Pietrasanta 3
Quận Một 3
Quận Phú Nhuận 3
Salt Lake City 3
Tel Aviv 3
Tianjin 3
Toronto 3
Turin 3
Vienna 3
Warsaw 3
Wuxi 3
Baghdad 2
Bonate Sopra 2
Brooklyn 2
Bắc Ninh 2
Catania 2
Chicago 2
Clarksville 2
Foshan 2
Houston 2
Hải Dương 2
Managua 2
Medina 2
Mexico City 2
Milan 2
Moscow 2
Nairobi 2
New Delhi 2
Ninh Bình 2
Pescara 2
Polignano a Mare 2
Quảng Ngãi 2
Quận Bình Thạnh 2
Richmond Hill 2
Salerno 2
Seattle 2
Shenzhen 2
Sofia 2
Sydney 2
Taurianova 2
Totale 1.318
Salva come PNG Salva come JPEG
Nome #
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 244
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 160
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 156
Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406] 131
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 124
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 118
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 111
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 109
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 91
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 91
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 88
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 86
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 86
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 81
The gustave roussy immune (Grim)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (nsclc) patients treated with first-line pembrolizumab 81
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 77
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 70
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 66
Non-small-cell lung cancer: how to manage EGFR-mutated disease 60
Totale 2.030
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.346
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.346
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20236 0 0 0 0 0 0 0 0 2 2 0 2
2023/202434 0 1 1 2 1 2 2 13 2 4 1 5
2024/2025513 5 42 59 27 74 17 39 24 10 37 56 123
2025/20261.383 234 155 116 114 99 61 134 42 182 107 63 76
2026/202794 53 41 0 0 0 0 0 0 0 0 0 0
Totale 2.030